ID Biomedical announces receipt of court approval for acquisition by GlaxoSmithKline
2005年12月7日 - 10:40AM
PRニュース・ワイアー (英語)
VANCOUVER, Dec. 6 /PRNewswire-FirstCall/ -- ID Biomedical
Corporation (TSX: IDB; NASDAQ: IDBE) ("ID Biomedical") announced
that today the British Columbia Supreme Court has approved the
proposed acquisition of ID Biomedical by GlaxoSmithKline plc and
GlaxoSmithKline Inc., including a change to the terms described in
ID Biomedical's management proxy circular (the "Circular") dated
October 18, 2005. Under the terms described in the Circular,
holders of 2003 warrants were to be paid Cdn.$5.33 for each warrant
held. Under the terms approved by the British Columbia Supreme
Court today, such holders will be entitled to receive Cdn.$9.20 for
each 2003 warrant held. Alternatively, such holders may choose to
exercise dissent rights and have the court fix the fair value of
their 2003 warrants. Details of the dissent rights, including
information on how to exercise such right, will be included in the
letter of transmittal for the 2003 warrantholders which is expected
to be mailed shortly. All other terms of the proposed transaction
remain unchanged and were approved by the court. Although
completion of the proposed transaction remains subject to a number
of conditions, ID Biomedical expects the transaction to be
completed prior to the end of 2005. About ID Biomedical ID
Biomedical is an integrated biotechnology company dedicated to the
development of innovative vaccine products. It operates in
research, development, manufacturing, sales and marketing from its
facilities in Canada and in the United States. ID Biomedical is
dedicated to becoming a premier vaccine company with significant
marketed products worldwide and an extensive pipeline in both
clinical and preclinical development. ID Biomedical has a leading
position in the Canadian influenza market. It received a ten year
mandate from the Government of Canada in 2001 to assure a state of
readiness in the case of an influenza pandemic and provide
influenza vaccine for all Canadians in such an event. It also
currently supplies approximately 75% of the Canadian government's
influenza vaccine purchases. The information in this news release
contains so-called "forward-looking" statements. These include
statements regarding ID Biomedical's expectations and plans
relating to the interaction of the vaccine business acquired from
Shire, statements about ID Biomedical's expectations, beliefs,
intentions or strategies for the future, which may be indicated by
words or phrases such as "anticipate", "expect", "intend", "plan",
"will", "we believe", "ID Biomedical believes", "management
believes", and similar language. All forward-looking statements are
based on ID Biomedical's current expectations and are subject to
risks and uncertainties and to assumptions made. Important factors
that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements include:
(i) the company's ability to successfully complete the proposed
GlaxoSmithKline transaction; (ii) the company's ability to
successfully complete preclinical and clinical development of its
products; (iii) the company's ability to manufacture its products;
(iv) the seasonality of the flu-vaccine business and related
fluctuations in the company's revenues from quarter to quarter; (v)
decisions, and the timing of decisions, made by the health
regulatory agencies regarding approval of its products for human
testing; (vi) the company's ability to enter into distribution
agreements for its products, and to complete and maintain corporate
alliances relating to the development and commercialization of its
technology and products; (vii) market acceptance of its
technologies and products; and (viii) the competitive environment
and impact of technological change and other risks detailed in the
company's filings with the Securities and Exchange Commission. ID
Biomedical bases its forward- looking statements on information
currently available to it, and assumes no obligation to update
them. For further information, please contact: Investor
Relations/Media Dean Linden Michele Roy (604) 431-9314 (450)
978-6313 DATASOURCE: ID Biomedical Corporation CONTACT: Investor
Relations, Media, Dean Linden, (604) 431-9314, ; Michele Roy, (450)
978-6313, ; To request a free copy of this organization's annual
report, please go to http://www.newswire.ca/ and click on Tools for
Investors.
Copyright